400-859-2883
Your location:Home >News center >Wonderful moment

Bepirovirsen Approved in Japan: A New Era of Functional Cure for Chronic Hepatitis B

Release time:2026/9/9 19:40:31
Author:Huateng

On August 24, 2026, GSK announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Hibsago (bepirovir…

On August 24, 2026, GSK announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Hibsago (bepirovirsen), an antisense oligonucleotide (ASO), for the treatment of chronic hepatitis B in adults who have received at least six months of prior nucleos(t)ide analogue therapy and meet predefined viral marker criteria. This is the first global approval of bepirovirsen and the first and only approved functional cure treatment for CHB in Japan. The approval marks an important milestone in the development of functional cure therapies for chronic hepatitis B. [1]

Why Functional Cure Matters in Chronic Hepatitis B

Chronic hepatitis B virus infection remains a major global health challenge and an important cause of cirrhosis and hepatocellular carcinoma. Although current antiviral therapies can effectively suppress HBV replication, achieving a durable functional cure remains difficult. Current standard-of-care therapies primarily involve nucleos(t)ide analogues (NAs) and pegylated interferon (PEG-IFN).

  • ● Nucleos(t)ide Analogues (NAs): NAs act by inhibiting the HBV reverse transcription step, but, since they do not directly target covalently closed circular DNA (cccDNA), a persistent viral DNA reservoir within infected hepatocytes, they seldom lead to HBV eradication, thus requiring long-term or even lifelong therapy, and relapse is common after cessation.

  • ● Pegylated Interferons (PEG-IFN): PEG-IFN exerts its effects by modulating both innate and adaptive immunity and can induce HBsAg decline or even clearance in a subset of patients.  Nevertheless, its clinical utility is constrained by poor tolerability, long treatment duration, and frequent adverse effects.

These limitations have driven the search for therapies that can move beyond continuous viral suppression toward a functional cure, defined as sustained undetectable viremia with durable HBsAg loss of at least 24 weeks after the end of therapy, with or without seroconversion to anti-HBsAg antibody.

Bepirovirsen (Hibsago) First Approval in Japan

GSK, in collaboration with Ionis Pharmaceuticals, developed Bepirovirsen (Hibsago), an antisense oligonucleotide (ASO) therapy licensed by GSK in 2019. Japan's Ministry of Health, Labour and Welfare (MHLW) has granted approval for Bepirovirsen as a functional cure treatment for adult patients with chronic hepatitis B who are receiving stable NA therapy.

The approval is supported by Phase 3 data from the primary B-Well program (B-Well 1 and B-Well 2), published in The New England Journal of Medicine (NEJM). The result shows that unprecedented functional cure rates of 19% in adults with HBsAg ≤3000 IU/ml, compared to current standard of care which typically only achieves a 1% functional cure rate annually. [2]

Bepirovirsen.jpg
Figure 1. B-Well program (B-Well 1 and B-Well 2) [2]

How Does Bepirovirsen Work?

Bepirovirsen illustrates the potential of antisense oligonucleotide technology to address multiple biological components of chronic HBV infection.

Viral RNA Degradation: As a 20-mer antisense oligonucleotide, Bepirovirsen selectively base-pairs with all HBV RNA transcripts, prompting RNase H-mediated cleavage to disrupt viral replication.

Surface Antigen Suppression: High serum levels of HBsAg induce T-cell exhaustion and immune tolerance. Bepirovirsen reduces the overall HBsAg antigen burden, relieving immune suppression.

Immune Activation: Preclinical evidence demonstrates that Bepirovirsen stimulates Toll-like receptor 8 (TLR8), aiding host immune restoration for sustained viral clearance after stopping therapy.

The Emerging Pipeline of RNA-Based Therapies for HBV

The approval of bepirovirsen is not an isolated development. A growing number of RNA-based and mechanism-driven therapies are being investigated for chronic hepatitis B.

The emerging pipeline includes antisense oligonucleotides, siRNA therapeutics, targeted GalNAc conjugates, capsid assembly modulators, and combination regimens designed to address different stages of the HBV life cycle.

CandidateDeveloperModalityKey Mechanism / TargetDevelopment Status
BepirovirsenGSK / IonisASOHBV RNA transcriptsApproved in Japan
Daplusiran/TomligisiranGSKGalNAc-siRNAHBV X and S ORFsPhase 2b
Imdusiran (AB-729)Arbutus BiopharmaGalNAc-conjugated RNAiHBV viral antigens / HBsAgPhase 2
Pevifoscorvir sodiumAligos TherapeuticsCAM-EHBV capsid assembly and viral lifecyclePhase 2

Daplusiran/Tomligisiran

Daplusiran/tomligisiran (DAP/TOM; formerly JNJ-3989 and also known as GSK5637608) is a GalNAc-conjugated siRNA therapeutic designed to target HBV RNA.

GSK is evaluating DAP/TOM in combination with bepirovirsen in the Phase 2b B-United study. The study is investigating sequential treatment with DAP/TOM followed by bepirovirsen in patients with chronic HBV receiving background nucleos(t)ide analogue therapy. Functional cure is the primary outcome of the study. [3]

The sequential approach illustrates a broader trend in HBV drug development: combining different mechanisms to first reduce the viral antigen burden and then promote durable immune-mediated control.

Imdusiran (AB-729)

Imdusiran is a GalNAc-conjugated RNA interference therapeutic developed by Arbutus Biopharma.

The therapy is designed to target hepatocytes and reduce HBV viral proteins and antigens, including HBsAg. Its GalNAc conjugation enables targeted delivery to hepatocytes following subcutaneous administration. [4]

Phase 2a studies have generated functional cure responses in selected patients when imdusiran was used in combination with nucleos(t)ide analogue therapy and immunomodulatory approaches. In 2026, the U.S. FDA granted Fast Track designation to imdusiran, and Arbutus reached alignment with the FDA on the design and safety parameters of a proposed Phase 2b study. [5]

The development of imdusiran highlights the increasing importance of GalNAc-mediated delivery in hepatocyte-targeted RNA therapeutics.

Pevifoscorvir Sodium (ALG-000184)

Pevifoscorvir sodium is an oral capsid assembly modulator (CAM-E) being developed by Aligos Therapeutics for chronic HBV infection.

Unlike ASOs and siRNAs, pevifoscorvir sodium acts through modulation of HBV capsid assembly and is designed to interfere with multiple stages of the viral lifecycle.

The Phase 2 B-SUPREME study compares pevifoscorvir sodium with tenofovir disoproxil fumarate in untreated adults with chronic HBV infection. The study has completed enrollment, with topline data expected in late Q3 2027. [6]

Although it is not an oligonucleotide therapeutic, its development illustrates the increasingly diversified approach to HBV drug development, in which different mechanisms may ultimately be combined to achieve deeper and more durable viral control.

From ASOs and siRNAs to Targeted Nucleic Acid Delivery

The development of bepirovirsen, imdusiran, and daplusiran/tomligisiran highlights several key trends in RNA drug development.

First, chemical modification is essential for improving the stability, activity, and pharmacological properties of oligonucleotide therapeutics.

Second, targeted delivery is becoming increasingly important. GalNAc conjugation, for example, enables selective delivery of siRNA therapeutics to hepatocytes, making the liver one of the most advanced target organs for conjugated RNA medicines.

Third, combination and sequential therapies are gaining momentum. Rather than relying on a single mechanism, future functional cure strategies may combine viral RNA suppression, antigen reduction, immune modulation, and other mechanisms targeting different components of HBV persistence.

These developments are expanding the role of nucleic acid chemistry from basic oligonucleotide synthesis toward increasingly sophisticated therapeutic design.

Supporting Next-Generation Nucleic Acid Drug Development

As a leading supplier of PEG derivatives and custom synthesis services, Huateng Pharma supports oligonucleotide and RNA therapeutic development worldwide. We provide high-purity raw materials and CDMO services, including:

  • PEG Linkers & Monodisperse Conjugates: Tailored for lipid nanoparticle (LNP) formulations and bioconjugation.

  • Custom Synthesis & Scale-Up: Comprehensive CDMO solutions from early-stage discovery to commercial-scale production under strict quality standards.

As RNA medicines continue to move toward more sophisticated molecular designs, reliable access to high-purity chemical building blocks and specialized synthesis capabilities will remain an important part of the development ecosystem.

 

References

1. GSK. Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B. August 24, 2026.

2. Hou J, Lim SG, Buti M, et al. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. New England Journal of Medicine. 2026;394:2395–2406. doi:10.1056/NEJMoa2515131.

3. GSK Study Register. B-UNITED: A Phase 2b study of sequential therapy with daplusiran/tomligisiran followed by bepirovirsen in participants with chronic hepatitis B.

4. Arbutus Biopharma. Imdusiran (AB-729): GalNAc-conjugated RNAi therapeutic for chronic hepatitis B.

5. Arbutus Biopharma. Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update. August 12, 2026.

6. Aligos Therapeutics. Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium. July 13, 2026.